BioSpace News Archive

As part of a massive nationwide effort to understand the condition commonly known as long COVID, Institute for Systems Biology is leading a multi-site Pacific Northwest consortium – http://www.pnwrecover.org/ – as part of the NIH-funded RECOVER initiative.

Kashiv Biosciences, LLC (“Kashiv”) today announced the U.S. Food and Drug Administration (FDA) approval of its Biologics License Application (BLA) for filgrastim-ayow, a biosimilar referencing Neupogen®.

OSSIO, Inc., an orthopedic fixation technology company, today announced that it has received a contract with Vizient, Inc., making the company’s portfolio of bio-integrative OSSIOfiber® products available at negotiated pricing to health care providers in Vizient’s group purchasing organization (GPO) under a three-year contract starting March 1.

Avenge Bio, Inc., (“Avenge” or the “Company”) a biotechnology company developing the LOCOcyte™ immunotherapy platform for the precision administration of potent immune effector molecules to treat solid tumors, today announced a publication in the peer-reviewed journal Science Advances describing the foundational, preclinical research establishing the LOCOcyte™.

MDxHealth SA, a commercial-stage precision diagnostics company, announced its financial results for the fourth quarter and year ended December 31, 2021 and provided a business update and outlook for 2022.

Adaptive Biotechnologies Corporation (“Adaptive Biotechnologies”) (Nasdaq: ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into clinical products to diagnose and treat disease, today announced it will be participating virtually in the upcoming 42nd Annual Cowen Healthcare Conference.

Motus GI Holdings, Inc. announced that its management team is scheduled to participate in two upcoming investor conferences in March 2022.

OrthoPediatrics Corp., a company focused exclusively on advancing the field of pediatric orthopedics, announced its financial results for the fourth quarter and full year ended December 31, 2021.

Delcath Systems, Inc. (Nasdaq: DCTH), an interventional oncology company focused on the treatment of primary and metastatic cancers of the liver, is pleased to announce that on February 28 its CHEMOSAT Hepatic Delivery System received Medical Device Regulation (MDR) certification under the new European Medical Devices Regulation [2017/745/EU].

Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, March 14 at 8:30 a.m. EST to provide a corporate update and report its financial results for fourth quarter and full year 2021.